Diego Cadavid, MD of Fulcrum Therapeutics explains the ongoing phase II clinical trial for facioscapulohumeral muscular dystrophy.
Facioscapulohumeral muscular dystrophy is a disabling disease characterized by progressive skeletal muscle loss. The rare disease generally begins with weakness in facial muscles but as the condition progresses, shoulders, arms and trunk, and eventually the rest of the body is affected.
Fulcrum Therapeutics is currently running a phase II clinical trial to test the safety and efficacy of losmapimod, a mitogen-activated protein kinase (MAPK) inhibitor, in persons with facioscapulohumeral muscular dystrophy.
To learn more about this and other rare neuromuscular disorders, visit checkrare.com/diseases/musculoskeletal-diseases/